{
    "nctId": "NCT03032614",
    "briefTitle": "Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients",
    "officialTitle": "Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Incidence, nature and severity of adverse events and serious adverse events, graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have archival biopsy specimens (preferably from metastatic disease) available for research tests. If a suitable biopsy specimen is not available, patients will be asked to undergo a research biopsy to procure tissue\n* Patients must be \\>/= 18 years\n* Females of childbearing potential must not have had unprotected sexual intercourse within 30 days prior to study entry and must agree to use a highly effective method of contraception. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation\n* Patients must have an ECOG performance status 0-1\n* Patients may have had a prior diagnosis of cancer if it has been \\> 5 years since their last treatment for that cancer\n* Patients must have normal organ and marrow function as defined below:\n\n  * Leukocytes \u2265 3,000/uL\n  * Absolute neutrophil count \u2265 1,500/uL\n  * Platelets \u2265 100,000/uL\n  * Creatinine within normal limits or creatinine clearance \u226530\n* Patients must be able to swallow and retain oral medication\n* Patients who were receiving prior systemic therapy: Prior treatment related side effects must have resolved to \\< Grade 2 severity (except alopecia and infertility)\n* All patients must have given signed, informed consent prior to registration on study\n* Patients must have stage IV breast or stage III and IV ovarian cancer (including platinum sensitive disease)\n* Patients must have BRCA1/2 deleterious mutations, PTEN deficiency, or cancer with a high HRD score as assessed by Myriad's assay\n* Patients must have measurable disease per RECIST 1.1 criteria (see above for definition)\n* Patients may not have received more than 3 chemotherapeutic regimens for metastatic disease\n* Patients may not have received treatment with prior carboplatin, eribulin or a PARP inhibitor\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating are not eligible\n* Patients who are undergoing concomitant radiotherapy are not eligible\n* Patients who are receiving any other investigational agents or concurrent anticancer therapy are not eligible\n* Previous systemic treatment is allowed with a 21 day washout period prior to registration\n* Patients who are taking any herbal (alternative) medicines are not eligible. Patients must be off any such medications by the time of registration\n* Patients with known brain metastases are not eligible for participation unless the following are met:\n\n  * Brain metastases are treated (either with surgical excision, stereotactic radiosurgery or radiotherapy and have been stable for at least 4 weeks (MRI documented)\n  * Patient is asymptomatic and has discontinued corticosteroids if taken for that purpose\n* Patients with any of the following conditions or complications are NOT eligible for participation:\n\n  * GI tract disease resulting in an inability to take oral medication\n  * Malabsorption syndrome\n  * Require IV alimentation\n  * History of prior surgical procedures affecting absorption\n  * Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).\n  * Hypersensitivity of any of the components of Veliparib, carboplatin, eribulin\n  * History of significant neurological (no neuropathy \\> Grade 2) or psychiatric disorders.\n  * Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).\n  * Significant non-neoplastic renal disease.\n  * Immunocompromised subjects, including subjects known to be infected with human immunodeficiency virus (HIV).\n  * Uncontrolled endocrine diseases (e.g., diabetes mellitus, hypothyroidism or hyperthyroidism, adrenal disorder) i.e., requiring relevant changes in medication within the last month or hospital admission within the last three months\n  * Active infection requiring systemic therapy.\n  * Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment.\n  * Prolongation of QTc interval to \\> 480 msec when electrolytes balance is normal.\n  * Major surgery within 4 weeks prior to the first dose of study drug",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}